Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance

Steroids

Volumn 111, Issue , 2016, Pages 95-99

  Yin, Li ^a,b   Wang, Zhao Yi ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Shenogen Pharma Group   (China)

Author keywords

Breast cancer; EGFR; ER 36; HER2; Tamoxifen resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; FULVESTRANT; LAPATINIB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTIESTROGEN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA, HUMAN;

BREAST CANCER CELL LINE; BREAST TUMOR; CANCER RESISTANCE; CANCER STEM CELL; DRUG RESISTANCE; DRUG SENSITIVITY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TAMOXIFEN;

EID: 84958568114     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2016.01.019     Document Type: Review

References (60)

1. J.I. Macgregor, and V.G. Jordan Basic guide to the mechanisms of antiestrogens action Phamacol. Rev. 50 1998 151 196
2. R. Clarke, F. Leonessa, J.N. Welch, and T.C. Skaar Cellular and molecular pharmacology of antiestrogens action and resistance Phamacol. Rev. 53 2001 25 71
3. R. Clarke, M.C. Liu, K.B. Bouker, Z.P. Gu, R.Y. Lee, Y.L. Zhu, T.C. Shaar, B. Gomez, K. O'Brien, Y. Wang, and L.A. Hilakivi-Clarke Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 22 2003 7316 7339
4. N. Normanno, M. Di Maio, E. De Maio, A. De Luca, Matteis Ad, A. Giordano, and F. Perrone Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer Endocr. Relat. Cancer 12 2005 721 747
5. L.C.J. Dorssers, S. van der Flier, A. Brinkman, T. van Agthoven, J. Veldscholte, E.M.J.J. Berns, J.G.M. Klijn, L.V.A.M. Beex, and J.A. Foekens Tamoxifen resistance in breast cancer: elucidating mechanisms Drugs 61 2001 1721 1733
6. C.K. Osborne, and R. Schiff Mechanisms of endocrine resistance in breast cancer Ann. Rev. Med. 62 2011 233 247
7. Z.Y. Wang, X.T. Zhang, P. Shen, B.W. Loggie, Y.C. Chang, and T.F. Deuel Identification, cloning and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α Biochem. Biophys. Res. Commun. 336 2005 1023 1027
8. Z.Y. Wang, X.T. Zhang, P. Shen, B.W. Loggie, Y.C. Chang, and T.F. Deuel A variant of estrogen receptor-α, hER-α36: transduction of estrogen and anti-estrogen dependent membrane-initiated mitogenic signaling Proc. Natl. Acad. Sci. U.S.A. 103 2006 9063 9068
9. Y. Zou, L. Ding, M. Coleman, and Z.Y. Wang Estrogen receptor-alpha (ER-α) suppresses expression of its variant ER-α36 FESEB Lett. 583 2009 1368 1374
10. L. Shi, B. Dong, Z.W. Li, Y.W. Lu, T. Ouyang, J.F. Li, T.F. Wang, Z.Q. Fan, T. Fan, B.Y. Lin, Z.Y. Wang, and Y.T. Xie Expression of ER-α36, a novel variant of estrogen receptor-α, and resistance to tamoxifen treatment in breast cancer J. Clin. Oncol. 27 2009 3423 3429
11. P.H. Driggers, and J.H. Segars Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling Trends Endocrinol. Metab. 13 2002 422 427
12. J.H. Segars, and P.H. Driggers Estrogen action and cytoplasmic signaling cascades. Part I: Membrane-associated signaling complexes Trends Endocrinol. Metab. 13 2002 349 354
13. M.J. Kelly, and E.R. Levin Rapid actions of plasma membrane estrogen receptors Trends Endocrinol. Metab. 12 2001 152 156
14. S.R. Hammes, and E.R. Levin Extranuclear steroid receptors: nature and actions Endocr. Rev. 28 2007 726 741
15. M. Razandi, A. Pedram, G.L. Greene, and E.R. Levin Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ER-alpha and ER-beta expressed in Chinese hamster ovary cells Mol. Endocrinol. 13 1999 307 319
16. K.S. Russell, M.P. Haynes, D. Sinha, E. Clerisme, and J.R. Bender Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling Proc. Natl. Acad. Sci. U.S.A. 97 2000 5930 5935
17. Z. Chen, I.S. Yuhanna, Z. Galcheva-Gargova, R.H. Karas, M.E. Mendelsohn, and P.W. Shaul Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen J. Clin. Invest. 103 1999 401 406
18. J.J. Watters, J.S. Campbell, M.J. Cunningham, E.G. Krebs, and D.M. Dorsa Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcription Endocrinology 138 1997 4030 4033
19. M. Razandi, A. Pedram, S.T. Park, and E.R. Levin Proximal events in signaling by plasma membrane estrogen receptors J. Biol. Chem. 278 2003 2701 2712
20. R.X. Song, Z. Zhang, Y. Chen, Y. Bao, and R.J. Santen Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells Endocrinology 148 2007 4091 4101
21. X.T. Zhang, L.G. Kang, L. Ding, S. Vranic, Z. Gatalica, and Z.Y. Wang A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells Oncogene 30 2001 770 780
22. L. Kang, Y.M. Guo, X.T. Zhang, and Z.Y. Wang A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells J. Steroid Biochem. Mol. Biol. 127 2011 262 268
23. X.T. Zhang, H. Deng, and Z.Y. Wang Estrogen activation of the mitogen-activated protein kinase is mediated by ER-alpha36 in ER-positive breast cancer cells J. Steroid Biochem. Mol. Biol. 143 2014 434 443
24. A. Migliaccio, G. Castoria, M. Di Domenico, A. de Falco, A. Bilancio, M. Lombardi, D. Bottero, L. Varricchio, M. Nanayakkara, A. Rotondi, and F. Auricchio Sex steroid hormones act as growth factors J. Steroid Biochem. Mol. Biol. 83 2002 31 35
25. M.A. Shupnik Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation Oncogene 23 2004 7979 7989
26. K.L. Troyer, and D.C. Lee Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network J. Mammary Gland Biol. Neoplasia 6 2001 7 21
27. R. Kumar, and R.A. Wang Protein kinases in mammary gland development and cancer Microsc. Res. Tech. 59 2002 49 57
28. G. Bunone, P.A. Briand, R.J. Miksicek, and D. Picard Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation EMBO J. 15 1996 2174 2183
29. S. Kato, H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, D. Metzger, and P. Chambon Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase Science 270 1995 1491 1494
30. A. Migliaccio, G. Castoria, M. Di Domenico, A. Ciociola, M. Lombardi, A. De Falco, M. Nanayakkara, D. Bottero, R. De Stasio, L. Varricchio, and F. Auricchio Crosstalk between EGFR and extranuclear steroid receptors Ann. N. Y. Acad. Sci. 1089 2006 194 200
31. E.R. Levin Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor Mol. Endocrinol. 17 2003 309 317
32. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
33. S. Chia, B. Norris, C. Speers, M. Cheang, B. Gilks, A.M. Grown, D. Huntsman, I.A. Olivotto, T.O. Nielsen, and K. Gelmon Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J. Clin. Oncol. 26 2008 5697 5704
34. C. Wright, B. Angus, S. Nicholson, J.R. Sainsbury, J. Cairs, W.J. Gullick, P. Kelly, and C.H. Harris Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer Cancer Res. 49 1989 2087 2090
35. M.D. Pegram, G. Pauletti, and D.J. Slamon HER-2/neu as a predictive marker of response to breast cancer therapy Breast Cancer Res. Treat. 52 1998 65 77
36. G. Li, J. Zhang, K. Jin, K. He, Y. Zheng, X. Xu, H. Wang, H. Wang, Z. Li, X. Yu, X. Teng, J. Cao, and L. Teng Estrogen receptor-α 36 is involved in development of Acquired Tamoxifen Resistance via regulating the growth status switch in breast cancer cells Mol. Oncol. 7 2013 611 624
37. X.T. Zhang, H. Deng, and Z.Y. Wang Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells J. Steroid Biochem. Mol. Biol. 143 2014 434 443
38. S. Vranic, Z. Gatalica, H. Deng, S. Frkovic-Grazio, M.J. Lee, O. Olga Gurjeva, and Z.Y. Wang ER-alpha36, a novel isoform of ER-alpha66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast J. Clin. Pathol. 64 2011 54 57
39. B.B. Tu, S.L. Lin, L.Y. Yan, Z.-Y. Wang, Q.Y. Sun, and J. Qiao ER-alpha36, a novel variant of estrogen receptor alpha, is involved in EGFR-related carcinogenesis in endometrial cancer Am. J. Obstet. Gynecol. 205 227 2011 e1 6
40. A. Ring, and M. Dowsett Mechanisms of tamoxifen resistance Endocr. Relat. Cancer 11 2004 643 658
41. L.G. Kang, and Z.Y. Wang Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36 J. Cell Mol. Med. 14 2010 1485 1493
42. X.T. Zhang, L. Ding, L.G. Kang, and Z.-Y. Wang Estrogen receptor alpha36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells PLoS ONE 7 2012 e30174
43. S.L. Lin, L.Y. Yan, X.T. Zhang, J. Yuan, M. Li, J. Qiao, Z.Y. Wang, and Q.Y. Sun ER alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways PLoS ONE 5 2010 e9013
44. C.K. Osborne, E.B. Coronado, and J.P. Robinson Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy Eur. J. Cancer Clin. Oncol. 23 1987 1189 1196
45. M.M. Gottardis, and V.C. Jordan Development of tamoxifen stimulated growth of MCF-7 tumors in athymic mice after a long-term antiestrogen administration Cancer Res. 48 1988 5183 5187
46. L. Yin, X.T. Zhang, X.W. Bian, Y.M. Guo, and Z.Y. Wang Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells PLoS ONE 9 2014 e107369
47. X.T. Zhang, and Z.Y. Wang Estrogen receptor-alpha variant, ER-alpha36, is involved in tamoxifen resistance and estrogen hypersensitivity Endocrinology 154 2013 1990 1998
48. C.C. Benz, G.K. Scott, J.C. Sarup, R.M. Johnson, D. Tripathy, E. Coronado, H.M. Shepard, and C.K. Osborne Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with her2/neu Breast Cancer Res. Treat. 24 1992 85 95
49. A. Wallacides, A. Chesnel, H. Ajj, M. Chillet, S. Flament, and H. Dumond Estrogens promote proliferation of the seminoma-like TCam-2 cell line through a GPER-dependent ERalpha36 induction Mol. Cell. Endocrinol. 350 2012 61 71
50. H. Kurokawa, and C.L. Arteaga Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer Clin. Cancer Res. 7 2001 4436s 4442s
51. C.X. Wang, D.C. Koay, A. Edwards, Z. Lu, G. Mor, I.T. Ocal, and M.P. DiGiovanna In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer Breast Cancer Res. Treat. 92 2005 251 263
52. I. Chu, K. Blackwell, S. Chen, and J. Slingerland The dual ErbB1 and ErbB2 inhibitor, Lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res. 65 2005 18 25
53. L. Yin, X.H. Pan, X.T. Zhang, Y.M. Guo, Z.Y. Wang, Y.Q. Gong, and M.L. Wang Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen. Am J. Cancer Res. 5 2015 530 544
54. M.X. Guo, M.L. Wang, X.Y. Zhang, H. Deng, and Z.Y. Wang Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells Anticancer Res. 33 2013 1873 1880
55. M.X. Guo, M.L. Wang, X.T. Zhang, H. Deng, and Z.Y. Wang A novel anticancer agent Broussoflavonol B downregulates ER-α36 expression and inhibits growth of ER-negative breast cancer MDA-MB-231 cells Eur. J. Pharmacol. 714 2013 56 64
56. L.R. Oliveira, S.S. Jeffrey, and A. Ribeiro-Silva Stem cells in human breast cancer Histol. Histopathol. 25 2010 371 385
57. H. Deng, X.T. Zhang, M.L. Wang, H.Y. Zheng, L.J. Liu, and Z.Y. Wang ER-alpha36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells PLoS ONE 2014 e88034
58. C.S. O'Brien, S.J. Howell, G. Farnie, and R.B. Clarke Resistance to endocrine therapy: are breast cancer stem cells culprits J. Mammary Gland Biol. Neoplasia 14 2009 45 54
59. M. Piva, G. Domenici, O. Iriondo, M. Rábano, B.M. Simões, V. Comaills, I. Barredo, J.A. López-Ruiz, I. Zabalza, and R. Kypta Sox2 promotes tamoxifen resistance in breast cancer cells EMBO Mol. Med. 5 2013 1 14
60. H. Deng, L. Yin, X.T. Zhang, L.J. Liu, M.L. Wang, and Z.Y. Wang ER-alpha variant ER-alpha 36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells J. Steroid Biochem. Mol. Biol. 144 2014 417 426